Not long ago, people diagnosed with mesothelioma had very few options. Most were limited to surgery, chemotherapy, or radiation, and new treatments felt far off. In the past few years, though, things have started to change. Immunotherapy, a treatment that helps the body’s own immune system find and attack cancer cells, offers new hope to patients and families who once had almost none.
While it’s not a cure, immunotherapy has changed the outlook for many people living with mesothelioma. For some, it’s added months or even years to life expectancy. For others, it’s improved quality of life and control over symptoms.
We’ll break down what immunotherapy actually is, how it works, the drugs that have been approved so far, and what’s coming next. For many families, it’s a real and growing reason to hope.
What Is Immunotherapy and How Does It Work?
For decades, standard cancer treatments like chemotherapy have worked by directly killing fast-growing cells, including healthy ones. Immunotherapy takes a different approach.[1] Instead of attacking the cancer itself, it trains the immune system to do what it was designed to do: find and destroy abnormal cells on its own.
One of the main ways it does this is through checkpoint inhibitors, which are drugs that release the natural “brakes” cancer puts on the immune system. These checkpoints are like security gates inside the body (called PD-1 and CTLA-4 pathways).
When mesothelioma cells flip these switches, they hide from immune attack. Immunotherapy drugs turn those switches back off, helping the immune system see the cancer again.
It’s a bit like reminding the body’s defense system what the enemy looks like. Once those defenses are reactivated, the immune system can fight back more effectively and, in some cases, keep the disease under control for years.
Immunotherapy has already become a standard part of treatment for cancers like melanoma and lung cancer. Now, it’s emerging as one of the most promising options for people with mesothelioma, offering new paths forward where few once existed.
FDA-Approved Immunotherapy Drugs for Mesothelioma
For years, researchers suspected that mesothelioma might respond to immune-based treatments, but progress was slow. That changed in 2020, when the U.S. Food and Drug Administration (FDA) approved a combination of two immunotherapy drugs, Opdivo (nivolumab) and Yervoy (ipilimumab), for people with unresectable pleural mesothelioma —meaning cases where surgery isn’t an option. [2]
How the Drugs Work Together
Opdivo and Yervoy are both checkpoint inhibitors, but they target different parts of the immune system:
- Opdivo (nivolumab) blocks the PD-1 pathway, which cancer cells use to “hide” from immune attack.
- Yervoy (ipilimumab) blocks the CTLA-4 pathway, thereby slowing T-cell activity.
By combining the two, doctors can activate immune cells on two different fronts, helping the body recognize and attack mesothelioma cells more effectively. You can think of it as lifting two sets of brakes at once, allowing the immune system to move forward again.
What the Results Show
In clinical trials, patients who received Opdivo and Yervoy lived longer on average than those who received standard chemotherapy.
- The median overall survival increased to about 18–19 months, compared to roughly 14 months for chemotherapy alone.
- Some patients experienced durable responses, meaning the treatment kept the disease under control for several years.
While not everyone responds the same way, these results marked a major step forward in mesothelioma care and are now a standard treatment option for many people diagnosed with the disease.
Managing Side Effects
Like most cancer treatments, immunotherapy can cause side effects, but they’re often different from those seen with chemotherapy.
Common issues include fatigue, rash, itching, diarrhea, or mild inflammation in organs such as the lungs or thyroid. Most of these effects are manageable, especially when caught early.
Doctors closely monitor patients during and after treatment, adjusting medications or temporarily pausing therapy if needed. The goal is always to balance effectiveness with comfort and safety, helping the immune system fight cancer without overwhelming the body.
Long-Term Benefits
One of the most promising aspects of immunotherapy is its potential for long-term immune control. For some patients, even after treatment ends, the immune system continues to recognize and suppress cancer cells. That means stable disease and, in some cases, years of added life, long after traditional treatments would have stopped working.
Who Is a Good Candidate for Immunotherapy?
Immunotherapy isn’t right for everyone, but it’s an important option for many people living with mesothelioma. Doctors usually recommend it for patients whose cancer can’t be removed with surgery or for those who have already completed chemotherapy and need another form of treatment.
Before starting, oncologists look at a few key factors:
- The cell type of the tumor, since some respond better than others
- A person’s overall health and how well their organs can handle treatment
- Immune markers, such as PD-L1 expression, help predict whether the immune system will recognize and attack the cancer.
No two cases are the same. The right treatment plan depends on your unique health, your type of mesothelioma, and how your body responds.
Combination Therapies and Clinical Trials
Doctors are finding that immunotherapy often works even better when it’s combined with other treatments. Right now, researchers are studying how it performs alongside a few key approaches.
- Chemotherapy, which can help shrink tumors and make it easier for the immune system to do its job
- Radiation therapy, which may expose hidden cancer cells and help the immune system recognize them
- Targeted or gene-based therapies, which zero in on the specific genetic changes that cause cancer cells to grow
These combinations are showing promise in early studies, and each new trial brings researchers one step closer to treatments that work longer and give patients more time.
The Future of Immunotherapy for Mesothelioma
Immunotherapy is still a relatively new field for mesothelioma, but research is moving fast.
Scientists are developing personalized vaccines that teach the immune system to recognize the unique mutations in each patient’s tumor. Others are studying CAR-T cell therapy, a process that re-engineers a person’s own immune cells to better target and destroy cancer.
Researchers are also searching for biomarkers, or biological “clues,” that can predict who is most likely to respond to treatment. These discoveries could make future therapies more precise and less likely to cause side effects.
Much of this progress comes from collaboration. Major cancer centers, universities, and pharmaceutical companies are working together to advance the science.
At Danziger & De Llano, we help clients secure the compensation they need to travel for specialized care or to participate in these cutting-edge clinical trials.
Taking the Next Step
If you’re considering immunotherapy, start by talking with your oncologist. Ask whether it could fit into your treatment plan or if there are clinical trials available for your type of mesothelioma. The more information you have, the more empowered you’ll feel to make decisions about your care.
Legal compensation can also make these treatments more accessible. It can help cover travel, lodging, and medical expenses, so you can focus on recovery rather than costs.
If You’re Exploring Treatment Options
If you or someone you love is considering treatment for mesothelioma, Danziger & De Llano can help you understand your legal rights and the resources available to support your care. Reach out to learn how compensation can ease the financial burden of treatment and give your family peace of mind while you focus on healing.
Frequently Asked Questions About Immunotherapy for Mesothelioma
1. What exactly is immunotherapy for mesothelioma?
Immunotherapy is a cancer treatment that helps your body’s own immune system find and attack cancer cells. Instead of killing cells directly like chemotherapy does, it “wakes up” the immune system so it can recognize mesothelioma cells that may have been hiding from it.
2. Which immunotherapy drugs are approved for mesothelioma?
The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was approved by the FDA in 2020 for people with pleural mesothelioma that can’t be removed with surgery. Together, these drugs help activate the immune system and have been shown to extend survival compared to chemotherapy alone.
3. How effective is immunotherapy for mesothelioma?
While results vary, studies show that people receiving Opdivo and Yervoy lived about 18–19 months on average, compared to roughly 14 months for those treated only with chemotherapy. Some patients have seen their disease remain stable for several years after treatment.
4. Who is a good candidate for immunotherapy?
Immunotherapy is often recommended for patients whose disease can’t be removed surgically or who have already completed chemotherapy. Doctors also consider tumor type, overall health, and certain immune markers before recommending it.
5. What side effects should I expect?
Common side effects include tiredness, mild rashes, itching, diarrhea, and inflammation in areas such as the lungs or thyroid. Most reactions can be managed with medication or short treatment breaks. Your doctor will monitor you closely to keep side effects under control.
6. Can immunotherapy be combined with other treatments?
Yes. Clinical trials are testing combinations of immunotherapy with chemotherapy, radiation, and targeted drugs. The goal is to improve treatment duration and reduce the risk of cancer recurrence.
7. How can I find immunotherapy clinical trials for mesothelioma?
You can ask your oncologist or a nurse navigator about ongoing trials at major cancer centers, or visit clinicaltrials.gov to search by location and cancer type. Many trials cover the cost of the drugs and additional care.
8. What’s next for mesothelioma immunotherapy research?
Researchers are working on personalized vaccines, CAR-T cell therapy, and gene-based immune treatments designed for each person’s tumor. Scientists are also studying biomarkers that predict who will respond best. These advances could make treatment more precise and effective.
9. How can legal compensation help with treatment costs?
Legal compensation from asbestos-related claims can help pay for travel to treatment centers, participation in clinical trials, and the high costs of new therapies. Danziger & De Llano help families access these funds so medical decisions aren’t limited by financial stress.
10. What should I do next if I’m interested in immunotherapy?
Start by speaking with your oncologist to see if immunotherapy could be part of your treatment plan. If you’d like to understand how legal compensation can make care more affordable, contact Danziger & De Llano for guidance.
Author: David Foster
Over the last 15 years, David has worked with the Dandell team to build a group of professionals whose goal is to make clients feel like their voices matter and that they are part of a family.
Reviewed by: Devan El Dana, PharmD
Medical Disclaimer: MesoCare.org provides educational information and is not a medical provider. We are not doctors. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician with any questions regarding a medical condition. Treatments mentioned are options that may help and should be discussed with a specialist.
Legal Disclaimer: MesoCare.org is a resource center and advocacy group, not a law firm. We do not provide legal advice or guarantee specific financial outcomes. No attorney-client relationship is formed by using this site or contacting an advocate. Potential compensation or grant amounts are estimates and vary by individual case.
Sources
[1] What is immunotherapy? (n.d.). American Cancer Society. https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy.html
[2] Immunotherapy for mesothelioma. (n.d.). American Cancer Society. https://www.cancer.org/cancer/types/malignant-mesothelioma/treating/immunotherapy.html
[3] Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A., Fujimoto, N., Tsao, A., Mansfield, A., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., & Zalcman, G. (n.d.). First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology, 33(5), 488–499. https://doi.org/10.1016/j.annonc.2022.01.074
[4] Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019). PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines & Immunotherapeutics, 15(5), 1111–1122. https://doi.org/10.1080/21645515.2019.1571892
[5] CAR T cell therapy shows promise for treating mesothelioma. (2025, July 1). Memorial Sloan Kettering Cancer Center. https://www.mskcc.org/news/car-cell-therapy-shows-promise-treatment-mesothelioma